Infectious Disease Specialist on Eli Lilly’s antibody treatment

Bob Sirott

FILE – This April 26, 2017, file photo shows the Eli Lilly & Co. corporate headquarters in Indianapolis. The drug company on Wednesday, Sept. 16, 2020, says that partial results from a study testing an antibody drug in mild to moderately ill COVID-19 patients give hints that the drug may help keep them from needing to be hospitalized, a goal no current coronavirus medicine has been able to meet. (AP Photo/Darron Cummings, File)

Dr. Aileen Marty, Infectious Disease Specialist and Professor at Florida International University, joined Bob Sirott to talk about the benefits behind Eli Lilly’s antibody treatment that has reduced the rate of hospitalization for coronavirus patients.

COVID-19 risk as determined by nonprofit Covid Act Now.

Coronavirus Resources from the CDC

Coronavirus by State

COVID-19 Testing Vs. Confirmed Cases by State

Interactive: Coronavirus Timeline

Bob Sirott
Weekdays 5-9am BobSirott

Bob Sirott's acclaimed broadcasting career has spanned nearly five decades and has included stints at WMAQ, WBBM-FM, WLS, WGN and various television stations. (Click for more.)
More Home Page Top Stories